Latest UCLA's Jonsson Comprehensive Cancer Center Stories
New method may help improve diagnosis, prognosis and treatment monitoring.
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death.
National Cancer Institute Chemical Biology Consortium to coordinate academic, private and government cancer drug discovery efforts BIRMINGHAM, Ala., Aug.
A new finding reveals that African-American patients with breast, ovarian, and prostate cancer tend to die earlier than patients of other races with these cancers, even when they receive identical medical treatment and when socioeconomic factors are controlled for.
Researchers at UCLA's Jonsson Comprehensive Cancer Center, on a quest to find lung cancer stem cells, have developed a unique model to allow further investigation into the cells that many believe may be at the root of all lung cancers.
FREMONT, Calif., April 23 /PRNewswire/ -- After a review of several vendors, the University of California Los Angeles (UCLA) has selected the services of Velos and its flagship product, Velos eResearch.
Oncologists often have to wait months before they can determine whether a treatment is working.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
A meta-analysis by Dutch researchers found cancer survivors -- especially women -- have a greater risk of unemployment. Angela G. E. M.
- Having no light.